 Charles River Laboratories Intl. NYSE:CRL was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report issued on Thursday, Zacks.com reports. According to Zacks, Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe ... 